Cognitive

DSIP (Delta Sleep-Inducing Peptide)

Nonapeptide · 9 amino acids · Neuropeptide

FDA · PRECLINICAL ONLY

Half-life

~8 minutes

Very short

minsdays

Route

SubQ injection

Evidence

Early human data

Risk

Moderate

Overview

Known for

Sleep peptide. Promotes delta wave (deep) sleep. May normalise disturbed sleep patterns rather than sedate. Also has stress-protective and analgesic properties. Works on sleep architecture rather than just inducing unconsciousness.

Mechanism

Neuropeptide that promotes delta wave (deep) sleep. Also has stress-protective, pain-modulating, and hormone-normalizing properties.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
Natural / Topping UpNatural
FDA category
Preclinical only

Evidence & standing

Evidence base
Early human data
Risk level
Moderate
Best studies
5 references
  • Schoenenberger & Monnier (1977) PNAS 74:1282-6 — Original discovery
  • Kovalzon & Strekalova (2006) Peptides 27:2738-52 — Review
  • Naturally occurring in human blood and brain tissue
  • NOT FDA APPROVED
  • Mixed clinical results — some studies show sleep benefit, others equivocal

Dosage & protocol

Typical dose
50-100mcg
Research range
100–300 µg
Cycle
As needed
Onset
2 days first effects
Full effect
21 days
Half-life
~7-8min
~7-8 minutes (very short)
Protocol

50-100mcg SubQ or intranasal before bed. Some use up to 250mcg.

Time to effects

EARLY: 1-3 nights

FULL: 2-4 weeks

Night 1-3: Improved sleep onset and depth. Many notice better sleep quality from the first dose.

Week 1-2: Normalised sleep architecture. More consistent deep sleep. Less nighttime waking.

Week 2-4: Cumulative effects — improved daytime energy from better sleep. Stress recovery improved.

Effects on sleep are felt quickly. Unlike sedatives, DSIP improves sleep QUALITY rather than just knocking you out. Minimum commitment: 2 weeks.

Recommended vial
  • 5mg vials

At 100mcg/night = 50 days ⚠️ exceeds 3-4 wk shelf life. At 250mcg/night = 20 days ✓. Use higher dosing. 10mg = much worse.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
Side effects

Headache, dizziness, mild sedation, vivid dreams. Limited safety data.

Interactions

Sedatives, benzodiazepines, opioids (additive CNS depression), alcohol

Do not combine
DermorphinDermorphin

Handle with research caution

  • Caution combining with other sedatives, benzodiazepines, or opioids (compounded CNS depression)

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
3–4 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.